Review



ctc immunofluorescence staining kit  (Cytelligen Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cytelligen Inc ctc immunofluorescence staining kit
    a The capture efficiency of different breast cell lines indicated that the <t>CTC</t> affinity interfaces could selectively capture several subtypes of breast cancer cells but not normal breast mammary epithelial cells ( n = 3 samples, mean ± s.d.). b Distinct difference in the enumeration of CTCs in 1 mL blood samples from healthy volunteers ( n = 10), benign patients ( n = 34), non-metastatic breast cancer (BC) patients ( n = 32), and metastatic BC patients ( n = 24). Unpaired two-sided Student’s t test. The central dot is the median; box bounds are 25th and 75th percentiles, upper and lower limits of whiskers are 1.5 × interquartile ranges. Values outside of the upper and lower limits are defined as outliers. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. c ROC analysis of CTC numbers between the cancer patient groups and healthy/benign groups. The receiver operating characteristic (ROC) curve showed good diagnostic performance (AUC = 0.991) in differentiating cancer patient groups and healthy/benign groups. d <t>Immunofluorescence</t> staining (DAPI/ER/HER2/CD45) of CTCs isolated from patients. Scale bar: 10 μm. CD45 was the biomarker for WBC and CK was the biomarker for CTC, with DAPI + /CK + /CD45 - cells recognized as CTCs and DAPI + /CK - /CD45 + cells identified as WBCs. ER and HER2 were used for the profiling of three subtypes of BC CTCs, including luminal (HER2 + or - /ER + ), HER2-positive (HER2 + /ER - ) and triple negative breast cancer (TNBC, belongs to basal-like subtype) (HER2 - /ER - ). 51 out of 56 molecular profiling results were in accordance with clinical diagnostic results. e Confusion matrix showing the subtyping accuracy of luminal, HER2, and TNBC by molecular profiling of CTCs. f Comparison of the CTC numbers isolated by A-f-M13-MB and CellSearch® or SE iFISH® in blood revealed a higher CTC capture ability and a better isolation performance of A-f-M13-MB in clinical applications. CellSearch® and SE iFISH® collected CTC from 7.5 mL and 6.0 mL blood, respectively, whereas our approach isolated CTC from 1.0 mL blood. A-f-M13-MB: Ni-IDA-MBs anchored with aptamer-modified-flexible M13; Source data are provided as a Source Data file.
    Ctc Immunofluorescence Staining Kit, supplied by Cytelligen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctc immunofluorescence staining kit/product/Cytelligen Inc
    Average 90 stars, based on 1 article reviews
    ctc immunofluorescence staining kit - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Harnessing virus flexibility to selectively capture and profile rare circulating target cells for precise cancer subtyping"

    Article Title: Harnessing virus flexibility to selectively capture and profile rare circulating target cells for precise cancer subtyping

    Journal: Nature Communications

    doi: 10.1038/s41467-024-50064-y

    a The capture efficiency of different breast cell lines indicated that the CTC affinity interfaces could selectively capture several subtypes of breast cancer cells but not normal breast mammary epithelial cells ( n = 3 samples, mean ± s.d.). b Distinct difference in the enumeration of CTCs in 1 mL blood samples from healthy volunteers ( n = 10), benign patients ( n = 34), non-metastatic breast cancer (BC) patients ( n = 32), and metastatic BC patients ( n = 24). Unpaired two-sided Student’s t test. The central dot is the median; box bounds are 25th and 75th percentiles, upper and lower limits of whiskers are 1.5 × interquartile ranges. Values outside of the upper and lower limits are defined as outliers. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. c ROC analysis of CTC numbers between the cancer patient groups and healthy/benign groups. The receiver operating characteristic (ROC) curve showed good diagnostic performance (AUC = 0.991) in differentiating cancer patient groups and healthy/benign groups. d Immunofluorescence staining (DAPI/ER/HER2/CD45) of CTCs isolated from patients. Scale bar: 10 μm. CD45 was the biomarker for WBC and CK was the biomarker for CTC, with DAPI + /CK + /CD45 - cells recognized as CTCs and DAPI + /CK - /CD45 + cells identified as WBCs. ER and HER2 were used for the profiling of three subtypes of BC CTCs, including luminal (HER2 + or - /ER + ), HER2-positive (HER2 + /ER - ) and triple negative breast cancer (TNBC, belongs to basal-like subtype) (HER2 - /ER - ). 51 out of 56 molecular profiling results were in accordance with clinical diagnostic results. e Confusion matrix showing the subtyping accuracy of luminal, HER2, and TNBC by molecular profiling of CTCs. f Comparison of the CTC numbers isolated by A-f-M13-MB and CellSearch® or SE iFISH® in blood revealed a higher CTC capture ability and a better isolation performance of A-f-M13-MB in clinical applications. CellSearch® and SE iFISH® collected CTC from 7.5 mL and 6.0 mL blood, respectively, whereas our approach isolated CTC from 1.0 mL blood. A-f-M13-MB: Ni-IDA-MBs anchored with aptamer-modified-flexible M13; Source data are provided as a Source Data file.
    Figure Legend Snippet: a The capture efficiency of different breast cell lines indicated that the CTC affinity interfaces could selectively capture several subtypes of breast cancer cells but not normal breast mammary epithelial cells ( n = 3 samples, mean ± s.d.). b Distinct difference in the enumeration of CTCs in 1 mL blood samples from healthy volunteers ( n = 10), benign patients ( n = 34), non-metastatic breast cancer (BC) patients ( n = 32), and metastatic BC patients ( n = 24). Unpaired two-sided Student’s t test. The central dot is the median; box bounds are 25th and 75th percentiles, upper and lower limits of whiskers are 1.5 × interquartile ranges. Values outside of the upper and lower limits are defined as outliers. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. c ROC analysis of CTC numbers between the cancer patient groups and healthy/benign groups. The receiver operating characteristic (ROC) curve showed good diagnostic performance (AUC = 0.991) in differentiating cancer patient groups and healthy/benign groups. d Immunofluorescence staining (DAPI/ER/HER2/CD45) of CTCs isolated from patients. Scale bar: 10 μm. CD45 was the biomarker for WBC and CK was the biomarker for CTC, with DAPI + /CK + /CD45 - cells recognized as CTCs and DAPI + /CK - /CD45 + cells identified as WBCs. ER and HER2 were used for the profiling of three subtypes of BC CTCs, including luminal (HER2 + or - /ER + ), HER2-positive (HER2 + /ER - ) and triple negative breast cancer (TNBC, belongs to basal-like subtype) (HER2 - /ER - ). 51 out of 56 molecular profiling results were in accordance with clinical diagnostic results. e Confusion matrix showing the subtyping accuracy of luminal, HER2, and TNBC by molecular profiling of CTCs. f Comparison of the CTC numbers isolated by A-f-M13-MB and CellSearch® or SE iFISH® in blood revealed a higher CTC capture ability and a better isolation performance of A-f-M13-MB in clinical applications. CellSearch® and SE iFISH® collected CTC from 7.5 mL and 6.0 mL blood, respectively, whereas our approach isolated CTC from 1.0 mL blood. A-f-M13-MB: Ni-IDA-MBs anchored with aptamer-modified-flexible M13; Source data are provided as a Source Data file.

    Techniques Used: Diagnostic Assay, Immunofluorescence, Staining, Isolation, Biomarker Assay, Comparison, Modification



    Similar Products

    ctc immunofluorescence staining kit  (Cytelligen Inc)
    90
    Cytelligen Inc ctc immunofluorescence staining kit
    a The capture efficiency of different breast cell lines indicated that the <t>CTC</t> affinity interfaces could selectively capture several subtypes of breast cancer cells but not normal breast mammary epithelial cells ( n = 3 samples, mean ± s.d.). b Distinct difference in the enumeration of CTCs in 1 mL blood samples from healthy volunteers ( n = 10), benign patients ( n = 34), non-metastatic breast cancer (BC) patients ( n = 32), and metastatic BC patients ( n = 24). Unpaired two-sided Student’s t test. The central dot is the median; box bounds are 25th and 75th percentiles, upper and lower limits of whiskers are 1.5 × interquartile ranges. Values outside of the upper and lower limits are defined as outliers. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. c ROC analysis of CTC numbers between the cancer patient groups and healthy/benign groups. The receiver operating characteristic (ROC) curve showed good diagnostic performance (AUC = 0.991) in differentiating cancer patient groups and healthy/benign groups. d <t>Immunofluorescence</t> staining (DAPI/ER/HER2/CD45) of CTCs isolated from patients. Scale bar: 10 μm. CD45 was the biomarker for WBC and CK was the biomarker for CTC, with DAPI + /CK + /CD45 - cells recognized as CTCs and DAPI + /CK - /CD45 + cells identified as WBCs. ER and HER2 were used for the profiling of three subtypes of BC CTCs, including luminal (HER2 + or - /ER + ), HER2-positive (HER2 + /ER - ) and triple negative breast cancer (TNBC, belongs to basal-like subtype) (HER2 - /ER - ). 51 out of 56 molecular profiling results were in accordance with clinical diagnostic results. e Confusion matrix showing the subtyping accuracy of luminal, HER2, and TNBC by molecular profiling of CTCs. f Comparison of the CTC numbers isolated by A-f-M13-MB and CellSearch® or SE iFISH® in blood revealed a higher CTC capture ability and a better isolation performance of A-f-M13-MB in clinical applications. CellSearch® and SE iFISH® collected CTC from 7.5 mL and 6.0 mL blood, respectively, whereas our approach isolated CTC from 1.0 mL blood. A-f-M13-MB: Ni-IDA-MBs anchored with aptamer-modified-flexible M13; Source data are provided as a Source Data file.
    Ctc Immunofluorescence Staining Kit, supplied by Cytelligen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctc immunofluorescence staining kit/product/Cytelligen Inc
    Average 90 stars, based on 1 article reviews
    ctc immunofluorescence staining kit - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    ctc immunofluorescence staining kit ifh-001  (Cytelligen Inc)
    90
    Cytelligen Inc ctc immunofluorescence staining kit ifh-001
    a The capture efficiency of different breast cell lines indicated that the <t>CTC</t> affinity interfaces could selectively capture several subtypes of breast cancer cells but not normal breast mammary epithelial cells ( n = 3 samples, mean ± s.d.). b Distinct difference in the enumeration of CTCs in 1 mL blood samples from healthy volunteers ( n = 10), benign patients ( n = 34), non-metastatic breast cancer (BC) patients ( n = 32), and metastatic BC patients ( n = 24). Unpaired two-sided Student’s t test. The central dot is the median; box bounds are 25th and 75th percentiles, upper and lower limits of whiskers are 1.5 × interquartile ranges. Values outside of the upper and lower limits are defined as outliers. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. c ROC analysis of CTC numbers between the cancer patient groups and healthy/benign groups. The receiver operating characteristic (ROC) curve showed good diagnostic performance (AUC = 0.991) in differentiating cancer patient groups and healthy/benign groups. d <t>Immunofluorescence</t> staining (DAPI/ER/HER2/CD45) of CTCs isolated from patients. Scale bar: 10 μm. CD45 was the biomarker for WBC and CK was the biomarker for CTC, with DAPI + /CK + /CD45 - cells recognized as CTCs and DAPI + /CK - /CD45 + cells identified as WBCs. ER and HER2 were used for the profiling of three subtypes of BC CTCs, including luminal (HER2 + or - /ER + ), HER2-positive (HER2 + /ER - ) and triple negative breast cancer (TNBC, belongs to basal-like subtype) (HER2 - /ER - ). 51 out of 56 molecular profiling results were in accordance with clinical diagnostic results. e Confusion matrix showing the subtyping accuracy of luminal, HER2, and TNBC by molecular profiling of CTCs. f Comparison of the CTC numbers isolated by A-f-M13-MB and CellSearch® or SE iFISH® in blood revealed a higher CTC capture ability and a better isolation performance of A-f-M13-MB in clinical applications. CellSearch® and SE iFISH® collected CTC from 7.5 mL and 6.0 mL blood, respectively, whereas our approach isolated CTC from 1.0 mL blood. A-f-M13-MB: Ni-IDA-MBs anchored with aptamer-modified-flexible M13; Source data are provided as a Source Data file.
    Ctc Immunofluorescence Staining Kit Ifh 001, supplied by Cytelligen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctc immunofluorescence staining kit ifh-001/product/Cytelligen Inc
    Average 90 stars, based on 1 article reviews
    ctc immunofluorescence staining kit ifh-001 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    ctc immunofluorescence staining kit ifh - 001  (Cytelligen Inc)
    90
    Cytelligen Inc ctc immunofluorescence staining kit ifh - 001
    a The capture efficiency of different breast cell lines indicated that the <t>CTC</t> affinity interfaces could selectively capture several subtypes of breast cancer cells but not normal breast mammary epithelial cells ( n = 3 samples, mean ± s.d.). b Distinct difference in the enumeration of CTCs in 1 mL blood samples from healthy volunteers ( n = 10), benign patients ( n = 34), non-metastatic breast cancer (BC) patients ( n = 32), and metastatic BC patients ( n = 24). Unpaired two-sided Student’s t test. The central dot is the median; box bounds are 25th and 75th percentiles, upper and lower limits of whiskers are 1.5 × interquartile ranges. Values outside of the upper and lower limits are defined as outliers. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. c ROC analysis of CTC numbers between the cancer patient groups and healthy/benign groups. The receiver operating characteristic (ROC) curve showed good diagnostic performance (AUC = 0.991) in differentiating cancer patient groups and healthy/benign groups. d <t>Immunofluorescence</t> staining (DAPI/ER/HER2/CD45) of CTCs isolated from patients. Scale bar: 10 μm. CD45 was the biomarker for WBC and CK was the biomarker for CTC, with DAPI + /CK + /CD45 - cells recognized as CTCs and DAPI + /CK - /CD45 + cells identified as WBCs. ER and HER2 were used for the profiling of three subtypes of BC CTCs, including luminal (HER2 + or - /ER + ), HER2-positive (HER2 + /ER - ) and triple negative breast cancer (TNBC, belongs to basal-like subtype) (HER2 - /ER - ). 51 out of 56 molecular profiling results were in accordance with clinical diagnostic results. e Confusion matrix showing the subtyping accuracy of luminal, HER2, and TNBC by molecular profiling of CTCs. f Comparison of the CTC numbers isolated by A-f-M13-MB and CellSearch® or SE iFISH® in blood revealed a higher CTC capture ability and a better isolation performance of A-f-M13-MB in clinical applications. CellSearch® and SE iFISH® collected CTC from 7.5 mL and 6.0 mL blood, respectively, whereas our approach isolated CTC from 1.0 mL blood. A-f-M13-MB: Ni-IDA-MBs anchored with aptamer-modified-flexible M13; Source data are provided as a Source Data file.
    Ctc Immunofluorescence Staining Kit Ifh 001, supplied by Cytelligen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctc immunofluorescence staining kit ifh - 001/product/Cytelligen Inc
    Average 90 stars, based on 1 article reviews
    ctc immunofluorescence staining kit ifh - 001 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a The capture efficiency of different breast cell lines indicated that the CTC affinity interfaces could selectively capture several subtypes of breast cancer cells but not normal breast mammary epithelial cells ( n = 3 samples, mean ± s.d.). b Distinct difference in the enumeration of CTCs in 1 mL blood samples from healthy volunteers ( n = 10), benign patients ( n = 34), non-metastatic breast cancer (BC) patients ( n = 32), and metastatic BC patients ( n = 24). Unpaired two-sided Student’s t test. The central dot is the median; box bounds are 25th and 75th percentiles, upper and lower limits of whiskers are 1.5 × interquartile ranges. Values outside of the upper and lower limits are defined as outliers. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. c ROC analysis of CTC numbers between the cancer patient groups and healthy/benign groups. The receiver operating characteristic (ROC) curve showed good diagnostic performance (AUC = 0.991) in differentiating cancer patient groups and healthy/benign groups. d Immunofluorescence staining (DAPI/ER/HER2/CD45) of CTCs isolated from patients. Scale bar: 10 μm. CD45 was the biomarker for WBC and CK was the biomarker for CTC, with DAPI + /CK + /CD45 - cells recognized as CTCs and DAPI + /CK - /CD45 + cells identified as WBCs. ER and HER2 were used for the profiling of three subtypes of BC CTCs, including luminal (HER2 + or - /ER + ), HER2-positive (HER2 + /ER - ) and triple negative breast cancer (TNBC, belongs to basal-like subtype) (HER2 - /ER - ). 51 out of 56 molecular profiling results were in accordance with clinical diagnostic results. e Confusion matrix showing the subtyping accuracy of luminal, HER2, and TNBC by molecular profiling of CTCs. f Comparison of the CTC numbers isolated by A-f-M13-MB and CellSearch® or SE iFISH® in blood revealed a higher CTC capture ability and a better isolation performance of A-f-M13-MB in clinical applications. CellSearch® and SE iFISH® collected CTC from 7.5 mL and 6.0 mL blood, respectively, whereas our approach isolated CTC from 1.0 mL blood. A-f-M13-MB: Ni-IDA-MBs anchored with aptamer-modified-flexible M13; Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Harnessing virus flexibility to selectively capture and profile rare circulating target cells for precise cancer subtyping

    doi: 10.1038/s41467-024-50064-y

    Figure Lengend Snippet: a The capture efficiency of different breast cell lines indicated that the CTC affinity interfaces could selectively capture several subtypes of breast cancer cells but not normal breast mammary epithelial cells ( n = 3 samples, mean ± s.d.). b Distinct difference in the enumeration of CTCs in 1 mL blood samples from healthy volunteers ( n = 10), benign patients ( n = 34), non-metastatic breast cancer (BC) patients ( n = 32), and metastatic BC patients ( n = 24). Unpaired two-sided Student’s t test. The central dot is the median; box bounds are 25th and 75th percentiles, upper and lower limits of whiskers are 1.5 × interquartile ranges. Values outside of the upper and lower limits are defined as outliers. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. c ROC analysis of CTC numbers between the cancer patient groups and healthy/benign groups. The receiver operating characteristic (ROC) curve showed good diagnostic performance (AUC = 0.991) in differentiating cancer patient groups and healthy/benign groups. d Immunofluorescence staining (DAPI/ER/HER2/CD45) of CTCs isolated from patients. Scale bar: 10 μm. CD45 was the biomarker for WBC and CK was the biomarker for CTC, with DAPI + /CK + /CD45 - cells recognized as CTCs and DAPI + /CK - /CD45 + cells identified as WBCs. ER and HER2 were used for the profiling of three subtypes of BC CTCs, including luminal (HER2 + or - /ER + ), HER2-positive (HER2 + /ER - ) and triple negative breast cancer (TNBC, belongs to basal-like subtype) (HER2 - /ER - ). 51 out of 56 molecular profiling results were in accordance with clinical diagnostic results. e Confusion matrix showing the subtyping accuracy of luminal, HER2, and TNBC by molecular profiling of CTCs. f Comparison of the CTC numbers isolated by A-f-M13-MB and CellSearch® or SE iFISH® in blood revealed a higher CTC capture ability and a better isolation performance of A-f-M13-MB in clinical applications. CellSearch® and SE iFISH® collected CTC from 7.5 mL and 6.0 mL blood, respectively, whereas our approach isolated CTC from 1.0 mL blood. A-f-M13-MB: Ni-IDA-MBs anchored with aptamer-modified-flexible M13; Source data are provided as a Source Data file.

    Article Snippet: Finally, the released cells were identified using CTC immunofluorescence staining kit (IFH-001, Cytelligen, USA).

    Techniques: Diagnostic Assay, Immunofluorescence, Staining, Isolation, Biomarker Assay, Comparison, Modification